or Try an Advanced Search...

    Technical Analysis for SNGX - Soligenix, Inc.

    Grade Last Price % Change Price Change
    F 0.40 -2.64% -0.01
    SNGX closed down 5.85 percent on Monday, April 22, 2024, on 20 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 13
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical SNGX trend table...
    Date Alert Name Type % Chg
    1,2,3 Pullback Bullish Bullish Swing Setup -2.64%
    Calm After Storm Range Contraction -2.64%
    NR7 Range Contraction -2.64%
    Narrow Range Bar Range Contraction -2.64%
    Inside Day Range Contraction -2.64%
    Wide Bands Range Expansion -2.64%
    Down 3 Days in a Row Weakness -2.64%
    Oversold Stochastic Weakness -2.64%
    Calm After Storm Range Contraction -8.33%
    Wide Bands Range Expansion -8.33%
    Older End-of-Day Signals for SNGX ...

       Recent Intraday Alerts

    Alert Time
    Down 3% 44 minutes ago
    Fell Below Previous Day's Low 44 minutes ago
    Down 2 % 44 minutes ago
    Down 1% 44 minutes ago
    Possible NR7 about 20 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    SNGX Chart by TradingView
    Basic chart:

    Profile

    Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ' (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Cancer Treatment Gastrointestinal Radiation Therapeutic Products Toxins Proteins Biodefense Biological Warfare Gastrointestinal Disease Lectins Biotherapeutic Products

    Is SNGX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 18 Soligenix stock dips on pricing $4.75 million securities offering
    Apr 18 Soligenix Announces Pricing of $4.75 Million Public Offering
    Apr 15 Why Is Penny Stock Soligenix Trading Higher On Monday?
    Apr 15 FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
    Apr 11 SNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte™…
    Apr 11 FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
    Apr 9 Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
    Apr 3 Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
    Mar 20 SNGX: Discussions Continue with FDA Regarding Second Phase 3 Study for HyBryte™ in CTCL…
    Mar 15 Soligenix GAAP EPS of -$0.79
    See more SNGX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.2
    52 Week Low 0.3705
    Average Volume 3,261,913
    200-Day Moving Average 0.59
    50-Day Moving Average 0.62
    20-Day Moving Average 0.49
    10-Day Moving Average 0.44
    Average True Range 0.08
    RSI (14) 33.77
    ADX 43.8
    +DI 32.40
    -DI 19.28
    Chandelier Exit (Long, 3 ATRs) 0.68
    Chandelier Exit (Short, 3 ATRs) 0.62
    Upper Bollinger Bands 0.63
    Lower Bollinger Band 0.35
    Percent B (%b) 0.19
    BandWidth 56.78
    MACD Line -0.06
    MACD Signal Line -0.06
    MACD Histogram 0.0009
    Fundamentals Value
    Market Cap 4.27 Million
    Num Shares 10.5 Million
    EPS -1.46
    Price-to-Earnings (P/E) Ratio -0.28
    Price-to-Sales 7.44
    Price-to-Book 1.65
    PEG Ratio -1.52
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.45
    Resistance 3 (R3) 0.45 0.44 0.44
    Resistance 2 (R2) 0.44 0.43 0.44 0.44
    Resistance 1 (R1) 0.42 0.42 0.42 0.42 0.44
    Pivot Point 0.41 0.41 0.41 0.41 0.41
    Support 1 (S1) 0.39 0.40 0.39 0.39 0.37
    Support 2 (S2) 0.38 0.39 0.38 0.37
    Support 3 (S3) 0.36 0.38 0.37
    Support 4 (S4) 0.36